https://www.thebodypro.com/author/calvin-cohen

Latest by Calvin Cohen, M.D., M.S.

Promo Image

Management of Treatment-Experienced Patients: A Summary of Key CROI 2008 Research

Table of Contents

Introduction Resistance CCR5 Inhibitors

Vicriviroc Maraviroc Tropism Assays

Raltegravir Etravirine Darunavir Footnotes

Introduction

At the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008), ...

Promo Image
News

NNRTIs: The Next Generation Approaches (Part I)

Part I

Introduction Mechanisms of NNRTI Activity and HIV NNRTI Resistance NNRTI Resistance in NNRTI-Naive and NNRTI-Experienced Individuals NNRTI Mutations: Resistance and Cross-Resistance NRTI Mutations: The Potential Impact on NNRTIs NNR...

Promo Image

NNRTIs: The Next Generation Approaches (Part II)

Case Study: Patient JD

JD is a 46-year-old gay male. He first learned of his HIV status in 1994 after a former partner with whom he had been in a three-year relationship discovered that he was HIV infected.

JD felt well when he was first tested for...

Promo Image

New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients

Introduction Epidemiology of HIV Resistance Predicting Treatment Response Based on Resistance Scores

Refinement of the Genotypic Resistance Score for Tipranavir
  The Value of Discussing Resistance Test Results With HIV Resistance Expe...
Promo Image

Substituting With Tenofovir Decreases the Adverse Effects Seen With Other NRTIs

Since the introduction of the antiviral tenofovir (TDF, Viread), there has been interest in using this drug in a variety of settings. One attractive feature of tenofovir is that it has a different, often reduced, adverse event profile compared to oth...

Promo Image

Tenofovir and Abacavir Do Not Interact in Patients on Triple-Nucleoside Regimens

Last year's 2nd IAS Conference in Paris will be remembered in part for the series of presentations showing the early failure of regimens containing the triple-nucleoside combination of lamivudine (3TC, Epivir), abacavir (ABC, Ziagen) and tenofovir (T...

Promo Image

Enfuvirtide Benefits Persist for at Least 2 Years

The TORO (T-20 versus Optimized Regimen Only) studies have been the primary sources of data on the new drug enfuvirtide (T-20, Fuzeon). Enfuvirtide -- the first and still the only available agent in the new, fourth class of antivirals called entry in...

Promo Image

Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients

Data from a study called BMS 045 was first presented in July 2003 at the International AIDS Society (IAS) meeting in Paris. This study involved 358 participants who had triple-class experience and resistance, and were randomized to receive a combinat...

Promo Image
Lipodystrophy/Body Fat

No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide

There has been a lot of concern regarding the contribution of many antivirals to changes in body shape -- specifically the changes in body fat called lipodystrophy. While enfuvirtide (T-20, Fuzeon) is an antiviral, it works by a completely different ...

Promo Image
Children (Ages 0-17)

Enfuvirtide Safe and Effective for Adolescents

This study was conducted to explore how well enfuvirtide (T-20, Fuzeon) would be tolerated by adolescents with HIV infection. The challenge is that enfuvirtide is given, like insulin, by self-injection. Those enrolled had prior antiviral experience i...